In the pharmaceutical field, magnesium citrate is mostly used in oral preparations, including osmotic laxative oral solutions and medicinal magnesium supplement preparations, which impose strict requirements on various indicators of the upstream synthetic raw material—food-grade magnesium oxide. Pharmaceutical-grade magnesium citrate not only requires chemical purity to meet standards, but also maintains high standards for impurities, ignition residues, and microorganism-related controls. As the reactive magnesium source, magnesium oxide serves as a critical checkpoint for controlling the quality of pharmaceutical-grade magnesium citrate.
Messi Biology possesses production experience and accumulations related to pharmaceutical excipients. Its pharmaceutical excipient-grade light magnesium oxide has completed registration and filing with the National Medical Products Administration (NMPA), and its food-grade magnesium oxide production workshop follows clean management protocols. These products can support the synthesis and processing of pharmaceutical-grade magnesium citrate, and the downstream magnesium citrate output can be used in the production of pharmaceutical intermediates such as bowel preparation formulations and auxiliary conditioning formulations for hypomagnesemia. The production of pharmaceutical-grade magnesium citrate does not permit magnesium oxide to introduce heavy metals or insoluble impurities; otherwise, these are difficult to completely remove in subsequent preparation stages, posing risks to medication safety. Messi Biology’s food-grade magnesium oxide undergoes multi-stage impurity removal processing, with each batch accompanied by complete physicochemical testing data, facilitating incoming inspection and quality traceability for pharmaceutical enterprises.
The reactivity of magnesium oxide directly dictates the synthesis reaction of pharmaceutical-grade magnesium citrate. If the reactivity of magnesium oxide is too high, the reaction will be violently exothermic, causing local temperatures to skyrocket, which may trigger side reactions and generate small amounts of byproduct salts. Conversely, if the reactivity is too low, the reaction conversion will be incomplete, leading to increased raw material consumption and higher production costs. Messi Biology can match magnesium oxide grades with suitable reactivity based on the reactor heat-transfer capacity and cooling system conditions of pharmaceutical clients, allowing the neutralization reaction to proceed smoothly and reducing byproduct formation. During the process upgrading and process validation stages for pharmaceutical enterprises, Messi Biology’s technical team can collaborate with clients to complete multiple sets of small-scale pilot comparisons to determine key parameters such as raw material grades and feeding rates. Guided by GMP-related system philosophies and holding over 150 patents, Messi Biology has participated in the revision of multiple national and industry standards. It is capable of providing stable, traceable magnesium source raw materials to pharmaceutical-grade magnesium citrate manufacturers, thereby reducing quality risks in pharmaceutical intermediate production.